Inify Laboratories - mandatory notification of trade

Stockholm - 19 December 2025 - Inify Laboratories AB (publ) (the "Company") announces that the below primary insider was allocated new shares at the subscription price in the private placement announced by the Company on 9 December 2025 (the "Private Placement"), as further specified in the attached notification forms: -          Gallivant S.à r.l. and Monsun AS, companies closely associated with board member Magne Jordanger, have been allocated 17,167,701 and 3,347,788 new shares, respectively, in the Private Placement (in aggregate: 20,515,489 new shares). Gallivant S.à r.l. and Monsun AS will, subject to completion of the Private Placement, own 64,578,361 and 11,391,684 shares, respectively, in the Company. For further information, please contact CEO, Fredrik Palm, fredrik.palm@inify.com, or visit https://www.inify.com. This information is subject to the disclosure requirements in the EU Market Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the Norwegian Securities Trading Act. ### The future of diagnostics Inify Laboratories offers diagnostics through specialised laboratory services in histopathology, with a focus on streamlining patient pathways. The company performs clinical diagnostics in prostate cancer and gastroenterology, providing an integrated service that spans from early sample handling to final diagnosis. The laboratory system is scalable both in handling large volumes of patient samples and for replicating in new locations. Quality and response times are optimised in every step - from logistics to tissue preparation and diagnosis - using a fully digital, standardised and AI -assisted workflow. The diagnosis is always performed by a pathologist and is assisted by Inify's proprietary AI, proven to have world-leading precision in clinical evaluations. The entire workflow is supported by a tailor-made system that also enables development to include additional diagnostic areas. Inify Laboratories is an international group headquartered in Stockholm, Sweden, with local laboratories in Sweden and the UK. The company's share is listed on Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103 -MERK) under the ticker INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)